SMT202400421T1 - Induzione del gene trail da parte di cellule normali e tumorali mediante una piccola molecola come terapia anticancro - Google Patents

Induzione del gene trail da parte di cellule normali e tumorali mediante una piccola molecola come terapia anticancro

Info

Publication number
SMT202400421T1
SMT202400421T1 SM20240421T SMT202400421T SMT202400421T1 SM T202400421 T1 SMT202400421 T1 SM T202400421T1 SM 20240421 T SM20240421 T SM 20240421T SM T202400421 T SMT202400421 T SM T202400421T SM T202400421 T1 SMT202400421 T1 SM T202400421T1
Authority
SM
San Marino
Prior art keywords
normal
tumor cells
small molecule
anticancer therapy
gene induction
Prior art date
Application number
SM20240421T
Other languages
English (en)
Italian (it)
Inventor
Wafik S El-Deiry
Gen Sheng Wu
Joshua E Allen
Original Assignee
Penn State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47068061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT202400421(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Penn State Res Found filed Critical Penn State Res Found
Publication of SMT202400421T1 publication Critical patent/SMT202400421T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SM20240421T 2011-04-29 2012-04-30 Induzione del gene trail da parte di cellule normali e tumorali mediante una piccola molecola come terapia anticancro SMT202400421T1 (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161480743P 2011-04-29 2011-04-29
EP20152317.2A EP3679934B1 (en) 2011-04-29 2012-04-30 Small molecule trail gene induction by normal and tumor cells as an anticancer therapy

Publications (1)

Publication Number Publication Date
SMT202400421T1 true SMT202400421T1 (it) 2024-11-15

Family

ID=47068061

Family Applications (2)

Application Number Title Priority Date Filing Date
SM20200272T SMT202000272T1 (it) 2011-04-29 2012-04-30 Induzione del gene trail da parte di cellule normali e tumorali mediante una piccola molecola come terapia anticancro
SM20240421T SMT202400421T1 (it) 2011-04-29 2012-04-30 Induzione del gene trail da parte di cellule normali e tumorali mediante una piccola molecola come terapia anticancro

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SM20200272T SMT202000272T1 (it) 2011-04-29 2012-04-30 Induzione del gene trail da parte di cellule normali e tumorali mediante una piccola molecola come terapia anticancro

Country Status (18)

Country Link
US (9) US8673923B2 (enExample)
EP (3) EP2701708B1 (enExample)
JP (7) JP6132833B2 (enExample)
CA (1) CA2832342C (enExample)
CY (1) CY1123010T1 (enExample)
DK (2) DK3679934T3 (enExample)
ES (2) ES2992934T3 (enExample)
FI (1) FI3679934T3 (enExample)
HR (2) HRP20241214T1 (enExample)
HU (2) HUE049207T2 (enExample)
LT (2) LT2701708T (enExample)
MX (2) MX365365B (enExample)
PL (2) PL2701708T3 (enExample)
PT (2) PT3679934T (enExample)
RS (2) RS60186B1 (enExample)
SI (2) SI2701708T1 (enExample)
SM (2) SMT202000272T1 (enExample)
WO (1) WO2012149546A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3679934T (pt) 2011-04-29 2024-09-05 Penn State Res Found Indução do gene trail de pequenas moléculas por células normais e tumorais enquanto terapia anticancro
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
WO2015073072A1 (en) * 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
BR112015023256A2 (pt) 2013-03-13 2017-07-18 Oncoceutics Inc terapia de combinação com 7-benzil-10-(2-metil-benzil)-2,6,7,8,9,10-hexaidroimidazol[1,2-a]pirido[4,3-d]pirimidin-5(3h)-ona.
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
CN106163524B (zh) * 2013-11-15 2019-11-08 昂克希尔迪克斯有限公司 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1H)-酮、其盐及应用方法
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
US11299528B2 (en) 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
SMT202400497T1 (it) 2014-03-31 2025-01-14 Scripps Research Inst Farmacoforo per induzione di trail
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
IL295286B2 (en) 2015-01-30 2024-10-01 Oncoceutics Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs thereof, and salts thereof and methods for their use in therapy
CN107405428A (zh) 2015-03-31 2017-11-28 北卡罗来纳-查佩尔山大学 干细胞的递送载体及其用途
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
WO2017106627A1 (en) 2015-12-17 2017-06-22 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
EP3408298B1 (en) 2016-01-29 2024-11-20 Oncoceutics, Inc. G protein-coupled receptor (gpcr) modulation by imipridones
CN109195620B (zh) 2016-04-07 2022-06-28 约翰霍普金斯大学 用死亡受体激动剂治疗胰腺炎和疼痛的组合物和方法
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
JP2025527300A (ja) 2022-08-05 2025-08-20 キメリックス インコーポレイテッド 神経膠腫の治療のための薬学的組成物及びその使用
WO2024102447A1 (en) * 2022-11-10 2024-05-16 Emory University Uses of hydroimidazopyridopyrimidinone derivatives for managing aneurysms or other vascular conditions or diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA105008A (en) 1907-02-06 1907-04-30 Charles B. Grimshaw Self-closing valve
DE2150062A1 (de) * 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
US5648097A (en) 1995-10-04 1997-07-15 Biotek, Inc. Calcium mineral-based microparticles and method for the production thereof
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
ES2357225T3 (es) * 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
WO2003055489A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
KR20080087822A (ko) * 2005-12-16 2008-10-01 제넨테크, 인크. 신경아교종을 진단하고, 예측하고, 치료하는 방법
JP5537035B2 (ja) * 2006-02-10 2014-07-02 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Ｃｄｋ阻害剤、および成長因子抗体または抗有糸分裂剤を含む組合せ
CN101511361A (zh) * 2006-06-30 2009-08-19 先灵公司 使用增强p53活性的取代哌啶的方法
JP5683462B2 (ja) * 2008-07-24 2015-03-11 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ オーロラキナーゼ阻害剤および抗増殖剤を含む治療用組み合わせ
PE20120559A1 (es) * 2009-06-24 2012-05-21 Stephen Evans-Freke Composicion que comprende al factor liberador de corticotropina
PT3679934T (pt) 2011-04-29 2024-09-05 Penn State Res Found Indução do gene trail de pequenas moléculas por células normais e tumorais enquanto terapia anticancro
BR112015023256A2 (pt) 2013-03-13 2017-07-18 Oncoceutics Inc terapia de combinação com 7-benzil-10-(2-metil-benzil)-2,6,7,8,9,10-hexaidroimidazol[1,2-a]pirido[4,3-d]pirimidin-5(3h)-ona.

Also Published As

Publication number Publication date
JP2021185210A (ja) 2021-12-09
RS60186B1 (sr) 2020-06-30
US9072744B1 (en) 2015-07-07
US8673923B2 (en) 2014-03-18
SI2701708T1 (sl) 2020-07-31
PL2701708T3 (pl) 2020-11-02
JP2019019145A (ja) 2019-02-07
WO2012149546A3 (en) 2013-01-03
JP2014514326A (ja) 2014-06-19
HRP20200636T1 (hr) 2020-07-10
SI3679934T1 (sl) 2025-04-30
PT2701708T (pt) 2020-05-08
MX379539B (es) 2025-03-11
JP6132833B2 (ja) 2017-05-24
EP3679934A1 (en) 2020-07-15
PL3679934T3 (pl) 2025-01-07
US9061032B2 (en) 2015-06-23
EP2701708A2 (en) 2014-03-05
US20220288079A1 (en) 2022-09-15
DK2701708T3 (da) 2020-04-27
CA2832342C (en) 2019-12-31
LT2701708T (lt) 2020-05-25
US20170224690A1 (en) 2017-08-10
EP3679934B1 (en) 2024-06-05
US20150265619A1 (en) 2015-09-24
JP7600286B2 (ja) 2024-12-16
MX365365B (es) 2019-05-30
ES2992934T3 (en) 2024-12-19
CY1123010T1 (el) 2021-10-29
USRE46290E1 (en) 2017-01-31
WO2012149546A2 (en) 2012-11-01
US9629842B2 (en) 2017-04-25
EP4335511B1 (en) 2025-11-26
JP2024051080A (ja) 2024-04-10
ES2786033T3 (es) 2020-10-08
DK3679934T3 (en) 2024-07-22
MX2019006379A (es) 2019-09-04
US20150202206A1 (en) 2015-07-23
US20170000790A1 (en) 2017-01-05
JP2025159099A (ja) 2025-10-17
US9452165B2 (en) 2016-09-27
JP2016199580A (ja) 2016-12-01
EP2701708A4 (en) 2015-01-07
EP2701708B1 (en) 2020-01-22
RS65813B1 (sr) 2024-08-30
FI3679934T3 (fi) 2024-07-08
LT3679934T (lt) 2024-11-11
JP2023060196A (ja) 2023-04-27
EP4335511A3 (en) 2024-05-15
SMT202000272T1 (it) 2020-07-08
HUE049207T2 (hu) 2020-09-28
EP4335511A2 (en) 2024-03-13
PT3679934T (pt) 2024-09-05
US20120276088A1 (en) 2012-11-01
MX2013012346A (es) 2014-08-22
HRP20241214T1 (hr) 2024-11-22
HUE068623T2 (hu) 2025-01-28
US20140248264A1 (en) 2014-09-04
US20240415841A1 (en) 2024-12-19
CA2832342A1 (en) 2012-11-01
US12036223B2 (en) 2024-07-16

Similar Documents

Publication Publication Date Title
DK3679934T3 (en) Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
IL231171A0 (en) RNA-derived t cells for cancer treatment
IL229649A0 (en) Dual direction
EP2673001A2 (en) Nts-polyplex nanoparticles system for gene therapy of cancer
EP2714090A4 (en) OBJECTIVE PEPTIDES AND METHOD THEREFOR
SG10201510009YA (en) Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer
HUE039389T2 (hu) Az anti-EMP2 terápia csökkenti a rák õssejteket
EP2585115A4 (en) CANCER THERAPY
EP2785870A4 (en) SMYD2 AS A TARGET GENE FOR ANTICANCER THERAPY AND THE DIAGNOSIS OF CANCER
EP2536741A4 (en) THERAPY TARGETING FUSIONS OF GENES
IL230987A0 (en) Targeted liposomes for cancer treatment
GB201106630D0 (en) Cancer therapy
GB201009217D0 (en) Targeted gene therapy
GB201118220D0 (en) Cancer therapy
AU2012904570A0 (en) Cancer therapy using miRNAs
IL229242A0 (en) Allogeneic cell vaccine for cancer
AU2012905122A0 (en) Combination therapy by lysosomal targeting
GB201020513D0 (en) Cancer therapy
GB201120096D0 (en) Novel therapy
GB201201397D0 (en) Gene targeting in animals
GB201100873D0 (en) Gene targeting in animals
ZA201208905B (en) Cancer therapy method
GB201109133D0 (en) Photodynamic therapy
AU2011901160A0 (en) Magnetic therapy headwear
EP2593113A4 (en) CELL THERAPY